Tesamorelin is the full 44-amino-acid GHRH sequence, modified to resist DPP-IV (which destroys native GHRH within minutes). Unlike exogenous HGH — which bypasses the pituitary and delivers a flat bolus — it stimulates your own GH in the pulsatile pattern your body uses during deep sleep, with the somatostatin brake intact (supraphysiological spikes are mechanistically difficult). FDA-approved in 2010 on two Phase III trials (816 patients): 15–20% visceral fat reduction vs placebo over 26 weeks, with improvements in triglycerides, waist, and liver fat. For context, sermorelin's adult data is 19 subjects and CJC-1295 no-DAC has zero human trials — the evidence gap is structural. The caveat: the fat comes back — patients who stopped at 26 weeks regained ~24.5% of visceral fat by week 52.
What Is Tesamorelin?
A synthetic GHRH analog (full 44-aa sequence) with a trans-3-hexenoic acid group protecting it from enzymatic breakdown. It doesn't add GH from outside; it stimulates the pituitary to release GH in its natural pulsatile pattern — turning up the volume on a signal the body already sends. Preserving pulsatility is central to its safety: the somatostatin negative-feedback brake still works (when GH/IGF-1 rise, somatostatin suppresses further release), which is not true for injected rhGH.
How Tesamorelin Works
It binds pituitary GHRH receptors on somatotrophs (cAMP/PKA pathway). Half-life is short (~8 min healthy, ~38 min steady-state in HIV patients) and SubQ bioavailability is <4% — it works through brief but potent receptor activation, not by lingering. Cascade: (1) pituitary activation → GH burst mimicking nocturnal pulses; (2) IGF-1 production in liver/tissues; (3) metabolic shift toward lipolysis (especially visceral fat) with enhanced protein synthesis/nitrogen retention; (4) feedback regulation via somatostatin. The net effect favors visceral-fat mobilization and lean-tissue preservation.
Clinical Evidence
The strongest evidence base of any GH secretagogue: two large double-blind placebo-controlled Phase III RCTs (816 combined patients).
| Outcome | LIPO-010 (N=412) | CTR-1011 (N=404) |
|---|---|---|
| VAT reduction vs placebo | -19.6% (CI -23.7 to -15.3) | -11.7% (CI -16.2 to -7.1) |
| Waist circumference | -1.8 cm vs placebo | -1.3 cm vs placebo |
| IGF-1 increase | ~106–109 ng/mL | ~106–109 ng/mL |
| Triglycerides | Statistically significant | Statistically significant |
Reduction is specific to visceral fat (minimal subcutaneous effect) because visceral adipocytes have higher GH-receptor density. A trial in HIV patients with MRI-confirmed NAFLD showed reduced hepatic fat and improved histology (less steatosis, slowed fibrosis), suggesting genuine liver-disease-modifying potential. The catch: in the 26–52 week extension, those who stopped regained ~24.5% of visceral fat by week 52 (difference vs continuers -25.8%, P=0.0008). It's an ongoing intervention — like a thermostat that drifts back when turned off — not a reset. All rigorous evidence is in HIV-associated lipodystrophy; every other application is off-label extrapolation.
Why It Matters for GLP-1 Users
GLP-1 agonists drive fat loss but provide no anabolic protection — 25–40% of weight lost can be lean mass. Tesamorelin supplies GH-pulsatility restoration, lean-mass preservation, and nitrogen retention during a deficit. Timing logic: GLP-1 effects peak in waking hours (mobilization); tesamorelin GH pulses peak during sleep (repair) — day for breakdown, night for protection.
Dosing
Reconstitute with isotonic (sodium-chloride) BAC water to reduce sting/welts; see the reconstitution calculator.
| Dose | 1–2 mg |
|---|---|
| Route | Subcutaneous (abdomen or thigh) |
| Timing | 30–60 min before bed, 2+ hours fasted |
| Cycle | 12–16 weeks on, 2–4 weeks off |
| Phase | Dose | Duration |
|---|---|---|
| Start | 1 mg nightly | 2–4 weeks |
| Increase | 2 mg nightly | If needed after 2–3 weeks |
| Adjust | EOD dosing | If IGF-1 runs high or side effects |
Week-8 checkpoint: get IGF-1 labs; target high-normal, not supraphysiologic. If IGF-1 exceeds 350–400 ng/mL, reduce dose. GLP-1 + tesamorelin protocol: weekly GLP-1, tesamorelin 1–2 mg SC before bed, resistance training 3–4×/week, protein 1.6–2.2 g/kg.
Side Effects and Safety
Generally manageable in trials: injection-site reactions (30–51% vs 21–24% placebo), myalgia (4–8%), fluid retention/edema (5–10%). Fluid retention is a GH-class effect (puffy fingers, ankle swelling, carpal-tunnel-like tingling) — dose-related and reversible. Glucose needs the most monitoring (GH is diabetogenic); a type-2-diabetes safety trial showed no major HbA1c/glucose worsening, but at-risk users should monitor. IGF-1 elevation is expected (~106–109 ng/mL); active cancer/high neoplasm risk is a contraindication. No cardiovascular, liver-toxicity, or HPTA-suppression signal.
Injection-site reactions
Unlike NAD+ (pH burn), tesamorelin triggers a histamine/mast-cell reaction — itchy raised welts, redness, warmth — that develops progressively (minimal weeks 1–3, welts weeks 4–5, consistent weeks 6–8). Mitigation: pre-dose H1 antihistamine (cetirizine/loratadine; reduces severity 50–70%), deeper injection (½" needle, 90°, into the fat pad, or switch to IM thigh), least-reactive sites (love handles often best), extra BAC water to dilute, and slow injection (30–60 s). Seek care for spreading welts, hives elsewhere, facial swelling/throat tightness/breathing difficulty, or hard/hot/pus sites (infection).
Tesamorelin vs HGH
| Feature | Tesamorelin | HGH |
|---|---|---|
| Mechanism | Stimulates endogenous GH release | Provides exogenous GH directly |
| GH pattern | Pulsatile (physiologic) | Sustained elevation |
| Feedback preserved | Yes (somatostatin brake intact) | No (bypasses feedback) |
| Risk of GH excess | Low (self-limiting) | Dose-dependent (can be significant) |
| FDA status | Approved (HIV lipodystrophy) | Approved (multiple indications) |
| Evidence for VAT | Phase III RCTs (N=816) | Limited for VAT specifically |
The trade-off is potency vs safety margin. Tesamorelin requires a functioning pituitary; for most people with intact pituitary function aiming to optimize rather than replace GH signaling, it offers a more physiologic approach with a wider safety margin.
Tesamorelin for Injury Recovery
Connective tissue consolidates during slow-wave sleep, when GH pulses trigger IGF-1-driven collagen synthesis. When that rhythm is disrupted (pain, poor sleep, stress, injury), tissue repairs but never fully consolidates — the "almost healed but keeps flaring" pattern with strength plateaued 10–15% below baseline. Tesamorelin is a timing peptide, not a healing peptide: it restores nocturnal GH pulsatility so existing repair consolidates during sleep. Use it when sleep is choppy and recovery feels random and structural repair (via BPC-157/TB-500) is already progressing; skip it if tissue is still cold/stiff (need more base repair) or energy crashes at rest (need NAD+ first). Injury dosing: 1–2 mg SubQ nightly, 30–60 min before sleep, 2+ h fasted, 8–12 week cycles; optional ipamorelin 200–500 mcg nightly added after 4 weeks to extend the GH-pulse window (mechanistically plausible, not directly validated). Do NOT mix with NAD+ (pH incompatible). Check IGF-1 at weeks 4 and 8.